Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

International, Multicenter, Randomized, Open-label, Phase II to Evaluate the Efficacy and Safety of Continuation of Palbociclib+2L Endocrine Therapy in HR+/HER2- ABC Patients Who Have Achieved Clinical Benefit During 1L Palbociclib

Next Previous
Search
Trial Profile

International, Multicenter, Randomized, Open-label, Phase II to Evaluate the Efficacy and Safety of Continuation of Palbociclib+2L Endocrine Therapy in HR+/HER2- ABC Patients Who Have Achieved Clinical Benefit During 1L Palbociclib

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Palbociclib (Primary) ; Fulvestrant; Letrozole
  • Indications Advanced breast cancer; Carcinoma; HER2 negative breast cancer
  • Focus Therapeutic Use
  • Acronyms PALMIRA

    • Most Recent Events

    • 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2023 According to a MEDSIR media release, data from this study was presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
    • 05 Jun 2023 Primary endpoint (PFS (Progression-free survival)) has not been met, according to a MEDSIR media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top